Unique genetic and risk-factor profiles in clusters of major depressive disorder-related multimorbidity trajectories DOI Creative Commons
András Gézsi, Sandra Van der Auwera, Hannu Mäkinen

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: Aug. 21, 2024

Abstract The heterogeneity and complexity of symptom presentation, comorbidities genetic factors pose challenges to the identification biological mechanisms underlying complex diseases. Current approaches used identify subtypes major depressive disorder (MDD) mainly focus on clinical characteristics that cannot be linked specific models. Here, we examined multimorbidities MDD with distinct non-genetic factors. We leveraged dynamic Bayesian network determine a minimal set relevant identified seven clusters disease-burden trajectories throughout lifespan among 1.2 million participants from cohorts in UK, Finland, Spain. had clear protective- risk-factor profiles as well age-specific courses driven by inflammatory processes, comprehensive map heritability correlations these was revealed. Our results can guide development personalized treatments for based unique genetic, patients.

Language: Английский

“Inflamed” depression: A review of the interactions between depression and inflammation and current anti-inflammatory strategies for depression DOI Creative Commons

Yishu Yin,

Ting Ju,

Deyong Zeng

et al.

Pharmacological Research, Journal Year: 2024, Volume and Issue: 207, P. 107322 - 107322

Published: July 20, 2024

Depression is a common mental disorder, the effective treatment of which remains challenging issue worldwide. The clinical pathogenesis depression has been deeply explored, leading to formulation various pathogenic hypotheses. Among these, monoamine neurotransmitter hypothesis holds prominent position, yet it significant limitations as more than one-third patients do not respond conventional treatments targeting transmission disturbances. Over past few decades, growing body research highlighted link between inflammation and potential key factor in pathophysiology depression. In this review, we first summarize relationship depression, with focus on pathophysiological changes mediated by mechanisms linking well multiple anti-inflammatory strategies are also discussed, their efficacy safety assessed. This review broadens perspective specific aspects using for treating laying groundwork advancing precision medicine individuals suffering from "inflamed"

Language: Английский

Citations

22
The characteristics of anhedonia in depression: a review from a clinically oriented perspective DOI Creative Commons
Congchong Wu, Qingli Mu, Weijia Gao

et al.

Translational Psychiatry, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 21, 2025

Anhedonia, as one of the core symptoms major depressive disorder (MDD), has been regarded a potential endophenotype disease. Multiple studies have evaluated mechanisms anhedonia in MDD, and found that MDD patients with showed different functions clinical features. In this review, we focus on research to explore differences between without manifestations biological alterations, elaborate treatments prognosis anhedonia. It is demonstrated associated adverse outcomes including more severe episode suicidality, poor MDD. At level, seem present higher levels inflammatory factors, abnormal metabolic function hypermetabolism BDNF. brain imaging studies, there are some structural and/ or functional changes multiple regions subcortical cortical areas, well limbic system Meanwhile, preliminary findings also indicated associations intestinal flora imbalance Moreover, evidence benefit selective serotonin reuptake inhibitors seemed limited anhedonia, other psychotherapy, physical therapy probiotic interventions remained be explored but interesting potential. Therefore, increased awareness anhedonic unique features would improved early diagnosis therapeutic effects

Language: Английский

Citations

4
Pathogenesis and treatment of depression: Role of diet in prevention and therapy DOI Creative Commons
Weronika Mrozek,

Justyna Socha,

Klara Sidorowicz

et al.

Nutrition, Journal Year: 2023, Volume and Issue: 115, P. 112143 - 112143

Published: June 28, 2023

In recent years, there has been a significant increase in depression, which is related to, among other things, the COVID-19 pandemic. Depression can be fatal if not treated or inappropriately. leading cause of suicide attempts. The disease multifactorial, and pharmacotherapy often fails to bring satisfactory results. Therefore, increasingly more importance attached natural healing substances nutrients food, significantly affect therapy process prevention depressive disorders. A proper diet vital preventing depression valuable addition psychological pharmacologic treatment. An inadequate may reduce effectiveness antidepressants their side effects, life-threatening symptoms. This study aimed review literature on pathogenesis development treatment with particular emphasis dietary supplements role nutrition

Language: Английский

Citations

42
Cardiovascular disease and depression: a narrative review DOI Creative Commons
Xinzhong Li, Jiahui Zhou, Min Wang

et al.

Frontiers in Cardiovascular Medicine, Journal Year: 2023, Volume and Issue: 10

Published: Nov. 21, 2023

In clinical practice, it is frequently observed that cardiac and psychological disorders co-occur, leading to the emergence of a field known as cardiovascular disease with depression. Depression, in particular, poses remarkable risk for evolution intimately relates adverse outcomes mortality. Moreover, individuals who are depressed exhibit higher susceptibility developing compared those good health. Patients diagnosed depression face heightened mortality within 5-year timeframe, their prognosis remains unsatisfactory even after receiving treatment targeting single disorder, notable recurrence rate. Psychological interventions conjunction medications commonly employed settings treating patients diseases, albeit limited effectiveness unfavorable prognosis. Traditional Chinese medicine (TCM), such Shuangxinfang, Chaihujialonggumuli, Yixin Ningshen Tablet, etc., have been reported Therapeutic effects combined Despite numerous articles documenting association between heart depression, there exists dearth studies elucidating precise pathogenesis target action diseases. This article endeavors consolidate epidemiological data, potential pathogenic mechanisms, available modalities Its primary objective unveil plausible co-morbid mechanisms suitable approaches, thereby offering novel insights prevention, diagnosis, management

Language: Английский

Citations

38
Mitochondrial Metabolism in Major Depressive Disorder: From Early Diagnosis to Emerging Treatment Options DOI Open Access
Ane Larrea, Laura Sánchez-Sánchez, Eguzkiñe Díez-Martín

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(6), P. 1727 - 1727

Published: March 17, 2024

Major Depressive Disorder (MDD) is one of the most disabling diseases in world. MDD traditionally diagnosed based on a patient’s symptoms, which can lead to misdiagnosis. Although pathogenic mechanisms are unknown, several studies have identified mitochondrial dysfunction as central factor onset and progression MDD. In context MDD, alterations metabolism imbalances energy production oxidative stress, contributing disorder´s underlying pathophysiological mechanisms. Consequently, identification key biomarker for early accurate diagnosis represents significant challenge. Faced with limits traditional treatments antidepressants, new pharmacological therapeutic targets being investigated such ketamine/esketamine, psychedelics, or anti-inflammatories. All these drugs show potential antidepressant effects due their speed action ability modulate neuroplasticity and/or motor processing. parallel, non-pharmacological studied, like Transcranial Magnetic Stimulation (TMS) Deep Brain (DBS), recognized neuronal activity offer treatment alternatives. As cellular directly related respiration, aim this review examining link between assessing how biomarkers could provide more objective precise diagnostic tool, exploring other addition specific focus emerging targets. Finally, detailed analysis strengths, weaknesses, opportunities, threats approaches was carried out, highlighting challenges that must be addressed.

Language: Английский

Citations

10
Lipidomics and genomics in mental health: insights into major depressive disorder, bipolar disorder, schizophrenia, and obsessive-compulsive disorder DOI Creative Commons
Martina Nicole Modesti, Jan Francesco Arena, Antonio Del Casale

et al.

Lipids in Health and Disease, Journal Year: 2025, Volume and Issue: 24(1)

Published: March 11, 2025

This systematic review explores the hypothesis that various lipid categories and metabolism-related genomic variations link to mental disorders, seeking potential clinically useful markers. We searched PubMed, Scopus, PsycInfo databases until October 12th, 2024, using terms related lipidomics, lipid-related genomics, different i.e., Major Depressive Disorder (MDD), Bipolar (BD), Schizophrenia (SCZ), Obsessive–Compulsive (OCD). Eligible studies were assessed. Extracted data included author, year, methodology, outcomes, genes, lipids linked disorders. Bias evidence certainty evaluated. The adhered PRISMA (Preferred Reporting Items for Systematic Reviews Meta-Analyses) guidelines a registered protocol (PROSPERO: CRD42023438862). A total of 27 included. SCZ showed alterations in 77 lipids, including triglycerides (TG), ceramides, phosphatidylcholine, while MDD BD exhibited 97 47 altered respectively, with overlap among Shared such as ABCA13, DGKZ, FADS, pathways involving inflammation, metabolism, mitochondrial function identified. OCD was associated sphingolipid signaling peroxisomal metabolism. Lipid signatures MDD, BD, shed light on underlying processes. Further research is needed validate biomarkers refine their clinical applications precision psychiatry.

Language: Английский

Citations

2
Association of hemoglobin-to-red blood cell distribution width ratio and depression in older adults: A cross sectional study DOI
Lijuan Xi, Fang Fang, Jiajie Zhou

et al.

Journal of Affective Disorders, Journal Year: 2023, Volume and Issue: 344, P. 191 - 197

Published: Oct. 11, 2023

Language: Английский

Citations

19
Advances in biosensors for major depressive disorder diagnostic biomarkers DOI
Tao Dong,

Chenghui Yu,

Qi Mao

et al.

Biosensors and Bioelectronics, Journal Year: 2024, Volume and Issue: 258, P. 116291 - 116291

Published: April 16, 2024

Language: Английский

Citations

9
Long Noncoding RNA VLDLR-AS1 Levels in Serum Correlate with Combat-Related Chronic Mild Traumatic Brain Injury and Depression Symptoms in US Veterans DOI Open Access
Rekha Patel, Meredith Krause‐Hauch, Kimbra Kenney

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(3), P. 1473 - 1473

Published: Jan. 25, 2024

More than 75% of traumatic brain injuries (TBIs) are mild (mTBI) and military service members often experience repeated combat-related mTBI. The chronic comorbidities concomitant with repetitive mTBI (rmTBI) include depression, post-traumatic stress disorder or neurological dysfunction. This study sought to determine a long noncoding RNA (lncRNA) expression signature in serum samples that correlated rmTBI years after the incidences. Serum were obtained from Long-Term Impact Military-Relevant Brain-Injury Consortium Chronic Effects Neurotrauma (LIMBIC CENC) repository, participants unexposed TBI who had rmTBI. Four lncRNAs identified as consistently present all samples, detected via droplet digital PCR packaged exosomes enriched for CNS origin. results, using qPCR, demonstrated lncRNA VLDLR-AS1 levels significantly lower among individuals compared those no lifetime TBI. ROC analysis determined an AUC 0.74 (95% CI: 0.6124 0.8741; p = 0.0012). optimal cutoff was ≤153.8 ng. A secondary clinical data LIMBIC CENC conducted evaluate psychological symptom burden, results show MALAT1 symptoms depression. In conclusion, may serve blood biomarker identifying depression patients.

Language: Английский

Citations

8
Transcutaneous auricular vagus nerve stimulation ameliorates adolescent depressive‐ and anxiety‐like behaviors via hippocampus glycolysis and inflammation response DOI Creative Commons
Lan Sun, Shixiang Ma, Yun Yu

et al.

CNS Neuroscience & Therapeutics, Journal Year: 2024, Volume and Issue: 30(2)

Published: Feb. 1, 2024

Transcutaneous auricular vagus nerve stimulation (taVNS) is a crucial neuromodulation therapy for depression, yet its molecular mechanism remains unclear. Here, we aim to unveil the underlying mechanisms of antidepression by systematically evaluating change gene expression in different brain regions (i.e., hippocampus, anterior cingulate cortex, and medial prefrontal cortex).

Language: Английский

Citations

7